Experimental Nuclear Medicine Meets Tumor Biology

Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Balber, Theresa, Tran, Loan, Benčurová, Katarína, Raitanen, Julia, Egger, Gerda, Mitterhauser, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878163/
https://www.ncbi.nlm.nih.gov/pubmed/35215337
http://dx.doi.org/10.3390/ph15020227
_version_ 1784658596832739328
author Balber, Theresa
Tran, Loan
Benčurová, Katarína
Raitanen, Julia
Egger, Gerda
Mitterhauser, Markus
author_facet Balber, Theresa
Tran, Loan
Benčurová, Katarína
Raitanen, Julia
Egger, Gerda
Mitterhauser, Markus
author_sort Balber, Theresa
collection PubMed
description Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence of different (pre)clinical disciplines that openly share their knowledge and methodologies. This review sheds light on the differential perception of biomarkers and gives an overview of currently used models in tracer development and approaches for biomarker discovery.
format Online
Article
Text
id pubmed-8878163
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88781632022-02-26 Experimental Nuclear Medicine Meets Tumor Biology Balber, Theresa Tran, Loan Benčurová, Katarína Raitanen, Julia Egger, Gerda Mitterhauser, Markus Pharmaceuticals (Basel) Review Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence of different (pre)clinical disciplines that openly share their knowledge and methodologies. This review sheds light on the differential perception of biomarkers and gives an overview of currently used models in tracer development and approaches for biomarker discovery. MDPI 2022-02-14 /pmc/articles/PMC8878163/ /pubmed/35215337 http://dx.doi.org/10.3390/ph15020227 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Balber, Theresa
Tran, Loan
Benčurová, Katarína
Raitanen, Julia
Egger, Gerda
Mitterhauser, Markus
Experimental Nuclear Medicine Meets Tumor Biology
title Experimental Nuclear Medicine Meets Tumor Biology
title_full Experimental Nuclear Medicine Meets Tumor Biology
title_fullStr Experimental Nuclear Medicine Meets Tumor Biology
title_full_unstemmed Experimental Nuclear Medicine Meets Tumor Biology
title_short Experimental Nuclear Medicine Meets Tumor Biology
title_sort experimental nuclear medicine meets tumor biology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878163/
https://www.ncbi.nlm.nih.gov/pubmed/35215337
http://dx.doi.org/10.3390/ph15020227
work_keys_str_mv AT balbertheresa experimentalnuclearmedicinemeetstumorbiology
AT tranloan experimentalnuclearmedicinemeetstumorbiology
AT bencurovakatarina experimentalnuclearmedicinemeetstumorbiology
AT raitanenjulia experimentalnuclearmedicinemeetstumorbiology
AT eggergerda experimentalnuclearmedicinemeetstumorbiology
AT mitterhausermarkus experimentalnuclearmedicinemeetstumorbiology

Ejemplares similares